Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Registration Trial of MAT9001 in Patients with Severe Hypertriglyceridemia

Trial Profile

A Phase 3 Registration Trial of MAT9001 in Patients with Severe Hypertriglyceridemia

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MAT 9001 (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Matinas BioPharma
  • Most Recent Events

    • 09 Mar 2020 According to a Matinas BioPharma media release, the company has completed the clinical dosing for a comparative clinical bridging bioavailability study and the in-life portion of a 90-day comparative toxicology study in the 1Q2020. Each of these studies was conducted in support of a planned 505(b)(2) registration pathwayThe Company anticipates holding an End-of-Phase 2 meeting with the U.S. FDA in the 3Q2020 to discuss these data as well as the protocol for this study.
    • 29 Nov 2013 New trial record
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top